Showing 261 - 280 results of 754 for search '"Pharmacokinetics"', query time: 0.06s Refine Results
  1. 261
  2. 262
  3. 263

    Is the GFR‐based scaling approach adequate for predicting pediatric renal clearance of drugs with passive tubular reabsorption? Insights from PBPK modeling by Sanwang Li, Xuexin Ye, Qiushi Wang, Zeneng Cheng, Feiyan Liu, Feifan Xie

    Published 2025-01-01
    “…Pediatric physiologically based pharmacokinetic (PBPK) modeling of metronidazole revealed that using a GFR‐based scaling method (Johnson model) significantly overestimated drug concentrations in children under 2 months, whereas utilizing the Mech‐KiM model for renal clearance predictions yielded estimates closely aligned with observed concentrations. …”
    Get full text
    Article
  4. 264
  5. 265

    Quantifying LAGA mutated mouse IgG2a monoclonal antibody with a rapid pepsin digestion enabled immunoaffinity LC/MS/MS assay by Linlin Dong, Susan Chen, Konstantin Piatkov, Dong Wei, Mark G. Qian

    Published 2024-12-01
    “…Consequently, a new pepsin digestion-based liquid chromatography-tandem mass spectrometry (LC/MS/MS) method was successfully developed to support the mouse pharmacokinetic (PK) sample analysis. In brief, robust and reproducible C-terminal cleavage of both leucine and phenylalanine near the double mutation site of the mutated mIgG2a was accomplished at pH ≤2 and 37°C. …”
    Get full text
    Article
  6. 266
  7. 267

    Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics by Guangqing Xiao, Liang-Shang Gan

    Published 2013-01-01
    “…In addition, the role of neonatal Fc receptor (FcRn) in regulating the efflux of Immunoglobulin G (IgG) from brain to blood, and approaches to improve the pharmacokinetics of therapeutic biologics by generating Fc fusion proteins, and increasing the pH dependent binding affinity between Fc and FcRn, are discussed.…”
    Get full text
    Article
  8. 268
  9. 269
  10. 270
  11. 271
  12. 272

    A model‐based approach using GSK3772847, an anti‐interleukin‐33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and... by Jan Berkhout, Dave Fairman, Martijn vanNoort, Tamara J. vanSteeg

    Published 2025-01-01
    “…Abstract Integrated modeling of the pharmacokinetic (PK) and target binding, by means of a TMDD model, can provide valuable insights into the expected pharmacodynamic (PD) effects of monoclonal antibodies (mAbs). …”
    Get full text
    Article
  13. 273

    Pharmacodynamic Profiling of Amoxicillin: Targeting Multidrug-Resistant Gram-Positive Pathogens <i>Staphylococcus aureus</i> and <i>Staphylococcus pseudintermedius</i> in Canine Cl... by Syed Al Jawad Sayem, Ga-Yeong Lee, Muhammad Aleem Abbas, Seung-Chun Park, Seung-Jin Lee

    Published 2025-01-01
    “…<b>Background/Objectives</b>: This study evaluates the effectiveness of amoxicillin against these MDR pathogens in canine isolates using pharmacokinetic and pharmacodynamic parameters. <b>Methods</b>: Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and mutation prevention concentration (MPC) were assessed. …”
    Get full text
    Article
  14. 274
  15. 275
  16. 276

    Improving breast cancer treatments using pharmacomicrobiomics by Aswin Anand Pai, Aadra Prashant Bhatt

    Published 2025-02-01
    “…Alam et al. introduce gut microbiota as a key factor influencing tamoxifen pharmacokinetics (Y. Alam, S. Hakopian, L. Ortiz de Ora, I. …”
    Get full text
    Article
  17. 277
  18. 278
  19. 279

    Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease by Wolfram Eisenreich, Bernd Sommer, Sebastian Hartter, Wolfgang H. Jost

    Published 2010-01-01
    “…The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-release formulation. …”
    Get full text
    Article
  20. 280